Clinico-radiological outcomes of desmoid type-fibromatosis after discontinuing the sorafenib treatment in responders – early results from the SORASTOP study
As per the early results, stopping sorafenib can be potentially considered in responding patients with stable extremity DTF after at least 1 year of treatment. With improvement in QoL and an acceptable rate of disease progression upon stopping sorafenib, this treatment discontinuation strategy could be an important consideration in DTF management. Further analysis of the entire study cohort is warranted to establish optimal treatment duration for extremity DTF.
Authors
- Shivanand Gamanagatti (ORCID: https://orcid.org/0000-0002-0145-4050)
- Vikas Garg (ORCID: https://orcid.org/0000-0002-9713-179X)
- Ghazal Tansir (ORCID: https://orcid.org/0000-0002-1045-7771)
- Bharath B Gangadharaiah
- Maroof Ahmad Khan (ORCID: https://orcid.org/0000-0001-9449-6518)
- Sandeep Bhoriwal (ORCID: https://orcid.org/0000-0002-9184-4254)
- Adarsh Barwad (ORCID: https://orcid.org/0000-0002-4805-3342)
- Sameer Rastogi
- Ekta Dhamija (ORCID: https://orcid.org/0000-0001-8265-9674)
- Simran Kaur (ORCID: https://orcid.org/0009-0006-2996-5887)
Institutions
- DR. B.R.A. Institute Rotary Cancer Hospital (IN)
- All India Institute of Medical Sciences (IN)
Publication Details
- Journal
- ecancermedicalscience
- Published
- 2025-05-27
- DOI
- https://doi.org/10.3332/ecancer.2025.1915
- Citations
- 2
- Primary Topic
- Soft tissue tumor case studies
- Type
- article
- Field-Weighted Citation Impact
- 3.34